PFKFB3 and metabolic dysfunction-associated steatotic liver disease: GDVs can also be used to treat non-alcoholic fatty liver disease (NAFLD), with their mechanism of action involving the inhibition of inflammatory reactions by regulating the expression of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3).